Clinical Trial Detail

NCT ID NCT01894672
Title BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan-Kettering Cancer Center
Indications

melanoma

Therapies

Encorafenib

Age Groups: senior adult

Additional content available in CKB BOOST